CA2775291A1 - Methods, compositions, and kits for reducing anti-antibody responses - Google Patents

Methods, compositions, and kits for reducing anti-antibody responses Download PDF

Info

Publication number
CA2775291A1
CA2775291A1 CA2775291A CA2775291A CA2775291A1 CA 2775291 A1 CA2775291 A1 CA 2775291A1 CA 2775291 A CA2775291 A CA 2775291A CA 2775291 A CA2775291 A CA 2775291A CA 2775291 A1 CA2775291 A1 CA 2775291A1
Authority
CA
Canada
Prior art keywords
allotypic
monoclonal antibody
subject
phenotype
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2775291A
Other languages
English (en)
French (fr)
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XBIOTECH Inc
Original Assignee
XBIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc filed Critical XBIOTECH Inc
Publication of CA2775291A1 publication Critical patent/CA2775291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2775291A 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses Abandoned CA2775291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24530509P 2009-09-24 2009-09-24
US61/245,305 2009-09-24
PCT/US2010/049924 WO2011038069A1 (en) 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses

Publications (1)

Publication Number Publication Date
CA2775291A1 true CA2775291A1 (en) 2011-03-31

Family

ID=43756813

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2775291A Abandoned CA2775291A1 (en) 2009-09-24 2010-09-23 Methods, compositions, and kits for reducing anti-antibody responses

Country Status (8)

Country Link
US (6) US20110071054A1 (https=)
EP (1) EP2480252A4 (https=)
JP (1) JP2013505938A (https=)
KR (1) KR20120093229A (https=)
CN (1) CN102573895A (https=)
AU (1) AU2010298264B2 (https=)
CA (1) CA2775291A1 (https=)
WO (1) WO2011038069A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2013505938A (ja) * 2009-09-24 2013-02-21 エックスバイオテク，インコーポレイテッド 抗抗体応答を軽減する方法、組成物およびキット
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP2014523884A (ja) * 2011-06-24 2014-09-18 セントローズ， エルエルシー 細胞外標的化薬物複合体
US20130089496A1 (en) * 2011-10-07 2013-04-11 Musc Foundation For Research Development Tumor targeted antibodies and method for using the same
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5856095A (en) * 1995-08-14 1999-01-05 St. Jude Children's Research Hospital Identification of two novel mutant alleles of human thiopurine S-methyltransferase, and diagnostic uses thereof
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
GB9925490D0 (en) * 1999-10-28 1999-12-29 Univ Cambridge Tech Binding molecules and treatment and screening methods
US20020127625A1 (en) * 2000-03-31 2002-09-12 Forskarpatent Is Syd Ab Methods of diagnosing immune related diseases
EP2288733A4 (en) * 2008-03-18 2012-03-21 Merck Sharp & Dohme PROTEIN CHANGE TEST WITH HIGH THROUGHPUT
JP2013505938A (ja) * 2009-09-24 2013-02-21 エックスバイオテク，インコーポレイテッド 抗抗体応答を軽減する方法、組成物およびキット

Also Published As

Publication number Publication date
KR20120093229A (ko) 2012-08-22
JP2013505938A (ja) 2013-02-21
US20120094395A1 (en) 2012-04-19
EP2480252A4 (en) 2014-04-30
AU2010298264B2 (en) 2014-10-23
US20120094301A1 (en) 2012-04-19
US20110071054A1 (en) 2011-03-24
WO2011038069A1 (en) 2011-03-31
US20110070230A1 (en) 2011-03-24
EP2480252A1 (en) 2012-08-01
US20110071276A1 (en) 2011-03-24
AU2010298264A1 (en) 2012-04-19
CN102573895A (zh) 2012-07-11
US20110070229A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
AU2010298264B2 (en) Methods, compositions, and kits for reducing anti-antibody responses
CN116496394B (zh) 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
JP2009515827A (ja) 治療薬
CN111153992A (zh) 结核分枝杆菌lam的单克隆抗体及其用途
CN116178529B (zh) 一株人源中和抗体或其抗原结合片段及其应用
CN117050178B (zh) 特异性检测il-7的抗体及应用
CN117088976B (zh) 一种抗nfl的单克隆抗体
CN112094346B (zh) 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体
CN112094352A (zh) 一种抗IgM单克隆抗体
Reyes et al. Broadly inhibitory antibodies against severe malaria virulence proteins
CN117069840B (zh) 特异性检测il-21的抗体及应用
CN115244079B (zh) 结合人ngf的抗体、其制备方法和用途
CN118240067B (zh) 抗腺病毒抗体、检测腺病毒的试剂和试剂盒
CN120865418B (zh) 抗ror1抗体及其应用
CN120623352B (zh) 抗human IgG的抗体、其制备方法及用途
CN118240068B (zh) 抗腺病毒抗体、检测腺病毒的试剂和试剂盒
US12188935B2 (en) Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
US20230061973A1 (en) Tat peptide binding proteins and uses thereof
US20210405026A1 (en) Method for evaluating the presence of a viral reservoir, and evaluating the efficacy of a drug against said reservoir
CN121758610A (zh) Tau蛋白289磷酸化位点特异性结合蛋白、阿尔兹海默症诊断试剂盒及其制备方法与应用
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases
KR20250122027A (ko) 고양이 혈청 아밀로이드 a 단백질에 대한 단일클론항체, 이를 생산하는 융합 세포주 및 이의 용도
JP2025514529A (ja) リンパ球の選択のための方法
CN120829514A (zh) 一种抗血型抗原的抗体及其应用
JP2009142269A (ja) ヒトＩｇＧのＦｃを含有するタンパク質の測定試薬

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150921

FZDE Dead

Effective date: 20190129